Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Rock Springs Capital

Founders Kris Jenner

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 139
Average round size
info
The average size of a deal this fund participated in
$107M
Portfolio companies 114
Rounds per year 12.64
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 69
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

The main department of described VC is located in the Baltimore. The company was established in North America in United States.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Medical, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight AveXis, Spark Therapeutics, Audentes Therapeutics. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Opposing the other organizations, this Rock Springs Capital works on 49 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2015. Deals in the range of 50 - 100 millions dollars are the general things for fund. The typical startup value when the investment from Rock Springs Capital is 500 millions - 1 billion dollars. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The fund is generally included in 7-12 deals every year. The top activity for fund was in 2015. Despite it in 2019 the fund had an activity.

Besides them, we counted 1 critical employee of this fund in our database.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Rock Springs Capital, startups are often financed by OrbiMed, Sofinnova Investments, Bay City Capital. The meaningful sponsors for the fund in investment in the same round are Deerfield, Wellington Management, Vivo Capital. In the next rounds fund is usually obtained by New Enterprise Associates, Omega Funds, CARB-X.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Rock Springs Capital:
Typical Co-investors
Rock Springs Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Rock Springs Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aivi Invest -
Bluegrass Angels Kentucky, Lexington, United States
California Institute for Regenerative Medicine California, San Francisco, United States
Cathexis Houston, Texas, United States
Changzhou Gaoxin Tou China, Jiangsu, Jintan
Disruptive Capital Finance England, London, United Kingdom
DMC Stratex Networks California, San Jose, United States
Higginbotham Strategic Investments -
Jumbo Sheen Group China, Guangdong, Shenzhen
Meta Capital -
Monarch Capital China, Hangzhou, Zhejiang
Movile Brazil, Paraíba, Sao Paulo
Presight Capital New City, New York, United States
Reti Televisive Italiane S.p.A. Cologno Monzese, Italy, Lombardia
The Good Stuff Beijing, Beijing, China
The Moinian Group New York, New York, United States
Tongcheng Zhongchuang Fund China, Jiangsu, Suzhou
Yabeo Capital Bavaria, Bayern, Germany
Zhongyan Chuangxin Touzi China, Guangdong, Shenzhen
Zhuhai Hecheng Zhiyi Ziben Guanli Youxian Gongsi China, Guangdong, Zhuhai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Apollo Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$33M02 Jan 2024 United Kingdom, England, United Kingdom

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$175M27 Sep 2023 Seattle, Washington, United States

Apollo Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$246M06 Sep 2023 United Kingdom, England, United Kingdom

Genesis Therapeutics

Artificial Intelligence
Biotechnology
Information Technology
$200M21 Aug 2023 South San Francisco, California, United States

Hemab

Biotechnology
Life Science
Pharmaceutical
$135M21 Feb 2023 Copenhagen, Capital Region of Denmark, Denmark

Zenas BioPharma

Biopharma
Health Care
Pharmaceutical
$118M07 Nov 2022 -

Treeline Biosciences

Biotechnology
Health Care
Life Science
$261M11 Oct 2022 Stamford, Connecticut, United States

Delfi Diagnostics

Biotechnology
Health Care
Health Diagnostics
$225M18 Jul 2022 Baltimore, Maryland, United States

Mineralys Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$118M08 Jun 2022 Radnor, Pennsylvania, United States
News
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Rock Springs Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 139
Average round size 107M
Rounds per year 12.64
Peak activity year 2021
Lead investments 8
Follow on index 0.18
Exits 69
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Apollo Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$33M02 Jan 2024 United Kingdom, England, United Kingdom

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$175M27 Sep 2023 Seattle, Washington, United States

Apollo Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$246M06 Sep 2023 United Kingdom, England, United Kingdom

Genesis Therapeutics

Artificial Intelligence
Biotechnology
Information Technology
$200M21 Aug 2023 South San Francisco, California, United States

Hemab

Biotechnology
Life Science
Pharmaceutical
$135M21 Feb 2023 Copenhagen, Capital Region of Denmark, Denmark

Zenas BioPharma

Biopharma
Health Care
Pharmaceutical
$118M07 Nov 2022 -

Treeline Biosciences

Biotechnology
Health Care
Life Science
$261M11 Oct 2022 Stamford, Connecticut, United States

Delfi Diagnostics

Biotechnology
Health Care
Health Diagnostics
$225M18 Jul 2022 Baltimore, Maryland, United States

Mineralys Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$118M08 Jun 2022 Radnor, Pennsylvania, United States
Crunchbase icon

Content report

The following text will be sent to our editors: